Atara Biotherapeutics (ATRA) Accumulated Expenses (2013 - 2026)

Atara Biotherapeutics has reported Accumulated Expenses for 14 years, with the latest figure at $629000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 93.38% year-over-year to $629000.0; the trailing twelve-month figure through Mar 2026 stood at $629000.0 (down 93.38% YoY), and the FY2025 full-year result was $1.8 million, down 70.17% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $629000.0, down from $1.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $19.0 million in Q4 2023, with the low at $629000.0 in Q1 2026.
• Historically, Accumulated Expenses has averaged $9.8 million across 5 years, with a median of $8.1 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 196.29% — and 2026, when it tumbled 93.38%.
• Atara Biotherapeutics' Accumulated Expenses stood at $17.7 million in 2022, then rose by 7.63% to $19.0 million in 2023, then plunged by 68.29% to $6.0 million in 2024, then slumped by 70.17% to $1.8 million in 2025, then tumbled by 65.02% to $629000.0 in 2026.
• The last three Accumulated Expenses figures came in at $629000.0 (Q1 2026), $1.8 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.